Page 6 - Pharma Companies

Jubilant Pharmova posts Q1 consolidated net profit of Rs 160 crore

Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 160.49 crore from continuing operations for the quarter ended June 30, 2021. The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing. Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added. Figures for the quarter are not comparable with previous periods since the Life Science Ingredients business was demerged with effect from February 1, 2021 pursuant to the composite scheme of arrangement during the previous year, the filing said. "During this quarter, in addition to YoY increase, we also reported sequential improvement in the specialty pharma segment with gradual recovery across radiopharmaceuticals, radiopharmacy and allergy business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said in a ...

Gland Pharma Q1 consolidated net profit up 12% to Rs 350.7 crore

Drug firm Gland Pharma on Wednesday reported an 11.83 percent increase in its consolidated net profit to Rs 350.7 crore for the quarter ended June 30, 2021, on account of robust sales in all markets.

Tatva Chintan Pharma IPO subscribed 4.51 times on first day of subscription

The initial public offer aggregating up to Rs 500 crore comprises a fresh issue of up to Rs 225 crore and an offer for sale of up to Rs 275 crore.

Abbott's Korea-imported PanBio Covid-19 self test launched at Rs 325

Firm expects demand from both, institutions and retail consumers, will import kits in 4-pack sizes from Korean plant; Test linked with NAVICA app which uploads results on ICMR website

MSN Labs enters into licence deal with DRDE for Covid-19 drug 2-DG

Drug firm MSN Laboratories on Friday said it has entered into a licence agreement with the Defence Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG), used for the treatment of COVID-19. Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, MSN Labs said in a statement. The company has entered into a licence agreement with DRDE and the Institute of Nuclear Medicine and Allied Sciences (INMAS) establishments of DRDO for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG) in India, it added. MSN labs will be launching the 2-DG as a twice-a-day product in sachet form under the brand name MSN 2D in strength of 2.34 g, the statement said.

Covid-19 crisis: Sputnik V, Moderna vaccines work against Delta variant

The protective proteins are called neutralizing antibodies because they're capable of preventing the virus from entering cells

Glenmark Pharma gets US health regulator nod for inhalation product

Glenmark Pharma said it received approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and emphysema, in the US market

How Biological E could emerge as game changer in India's vaccine race

Company scales up its ambition after government advanced it Rs 1,500 crore for 300 million doses of its vaccine candidate.

Hope to launch diabetic NCE by next financial year: Torrent Pharma's Mehta

We would also look into distribution opportunities to bring some of these products into the market, said Mehta

Bharat Biotech, Ocugen extend agreement to market Covaxin in Canada

Phase 3 analysis data to be submitted to WHO soon for EUL

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The medicines are a therapeutic equivalent of Banzel®

Moderna says its Covid-19 vaccine is up to 100% effective in teens

Company will submit data for regulatory authorisation in early June

AstraZeneca Pharma India Q4 net profit up nearly 3-fold to Rs 27.27 cr

Drug firm AstraZeneca Pharma India on Tuesday reported a nearly three-fold jump in its net profit to Rs 27.27 crore for the quarter ended March 31, 2021. The company had posted a net profit of Rs 9.57 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing. Revenue from operations of the company stood at Rs 210.25 crore for the quarter under consideration. It was Rs 194.90 crore for the same period a year ago, it added. For the financial year ended March this year, the net profit of the company was Rs 93.30 crore as against Rs 72.22 crore for the previous financial year, the filing said. The company's revenue from operations stood at Rs 813.56 crore for the financial year ended March 31, 2021. It was Rs 831.80 crore for the year-ago fiscal, it added. Shares of AstraZeneca Pharma India closed at Rs 3,862.45 per scrip on BSE, up 0.84 percent from its previous close.

Natco starts phase-3 trials of Molnupiravir capsules for Covid-19 treatment

Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patients with mild COVID-19.

Five pharmaceutical companies get approval to make black fungus drug

These developments come amid fast spread of the disease in various states and shortage of drugs to treat them.

Retail investors miss rally in Gland Pharma; stock up 118% over IPO price

At the time of its IPO, retail investors bid for only 24 per cent or 0.24 times of the shares set aside for them

More pharma firms should be allowed to make vaccine: Nitin Gadkari

Union Minister Nitin Gadkari on Tuesday suggested that more pharma companies should be allowed to make the COVID-19 vaccine in the country during the pandemic to scale up production.

Additional 45,000 vials of tocilizumab allocated to states: Gowda

Union Minister Sadananda Gowda on Tuesday said additional 45,000 vials of tocilizumab, used for treatment of Covid-19, have been allocated to states and union territories to meet the increased demand.

FabiFlu numero uno in Indian pharma market, show April sales data

With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore

After just Rs 18,000 cr profits in a decade, Serum, Bharat Biotech may earn big with Covid

For both companies, the pandemic presents a once-in-a-lifetime opportunity to earn hundreds of crores of rupees that could be ploughed back to fund further research and capacity expansion